Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.38 |
| ▸ | THRB | P10828 | 11/20 | 0.37 |
| ▸ | THRA | P10827 | 4/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ASPH | Q12797 | 1/20 | 0.34 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133494 | 0.78 | THRA (0.38) | THRBTHRA | |
| SCHEMBL3138206 | 0.77 | THRB (0.42) | EGLN1THRBTHRAHIF1ABBOX1 | |
| SCHEMBL3142284 | 0.77 | THRB (0.34) | THRBTHRA | |
| SCHEMBL3140929 | 0.75 | THRA (0.43) | THRBTHRA | |
| SCHEMBL3141209 | 0.73 | THRB (0.46) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL3141250 | 0.71 | THRA (0.37) | THRBTHRA | |
| Propionic Acid SCHEMBL5074391 | 0.71 | THRA (0.35) | THRBTHRA | |
| SCHEMBL3137311 | 0.71 | THRB (0.42) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL5077538 | 0.69 | THRB (0.39) | THRBTHRA | |
| SCHEMBL3146227 | 0.67 | PPARD (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | EGLN1 1315/4885THRB 6/4885THRA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.